SecBot SecBot
SECBOTREPLAY Home › Report › XNCR

XNCR · Xencor reported final Phase 1 data for XmAb942, an anti-TL1A antibody…

Xencor Inc · 8-K filed May 5, 2026 at 08:41 ET

At the news

BULLISHIMPACT 7/10

8-K filed May 5, 2026 at 08:41 ET

Xencor reported final Phase 1 data for XmAb942, an anti-TL1A antibody for IBD, showing a terminal half-life of 74.1 days, favorable safety, and low immunogenicity (0% neutralizing antibodies at target dose). The company also presented preclinical data for XmAb412, a TL1A x IL23p19 bispecific, with predicted human half-life of 60-70 days. Enrollment in the Phase 2b XENITH-UC study remains on track with a blinded interim analysis expected around year-end 2026 and primary endpoint results in 2H27.

  • XmAb942 Phase 1 estimated terminal half-life of 74.1 days from pooled single-dose cohorts
  • 0% neutralizing antibodies (NAb+) at XENITH-UC target dose regimen; 25% ADA+ at target dose
  • 86% of patients predicted to achieve >99% TL1A inhibition at induction (Week 12) per QSP model
  • 90% of patients predicted to achieve >90% TL1A inhibition at maintenance (Week 52) with Q12W SC dosing

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access